Is Cardiff Oncology, Inc. (CRDF) a Buy, Sell, or Hold?
NASDAQ : CRDF
Cardiff Oncology, Inc.
$0.8903 USD
$0.0 (0.11%)
- Volume
- 1.19M
- Average Volume
- 1.41M
- Market Capitalization
- $60.87M
- P/E Ratio
- -1.33
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $4.56
- Year Low
- $0.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.27
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Mani Mohindru |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRDF |
| CUSIP | 14147L108 |
| CIK | 0001213037 |
| Web | https://www.cardiffoncology.com |
| Phone | 858 952 7570 |
| Currency | USD |
| Employees | 31 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.27 |
| Quick Ratio | 3.27 |
| Cash Ratio | 0.59 |
Sales & Book Value
| Annual Sales | $593K |
| Price / Sales | 115.94 |
| Cash Flow | -0.55 |
| Price / Cash Flow | -1.62 |
| Price / Book | 1.75 |
Price Target and Rating
| Average Stock Price Forecast | $2.00 |
| High Stock Price Forecast | $2.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | -55.49% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.69 |
| Trailing P/E Ratio | -1.33 |
| PEG Ratio | -0.04 |
| P/E Growth | -0.04 |
| Net Income | -$45.85M |
| Net Margin | -8526.10% |
| Pretax Margin | -8526.10% |
| Return on Equity | -95.50% |
| Return on Assets | -91.03% |
Financials Score
| AltmanZ Score | -12.18 |
| Piotroski Score | 2.00 |
| Working Capital | 32.88M |
| Total Assets | 49.17M |
| Ebit | -44.76M |
| Market Cap | 62.9M |
| Total Liabilities | 14.46M |
Poll Results
About Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients ... with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Cardiff Oncology Announces $10 Million Registered Direct Offering
2026-07-15 08:00:00
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,571,429 shares of its common stock and accompanying warrants to purchase up to an aggregate of 8,571,429 shares of its common stock, at a purchase price of $1.05 per share and accompanying warrant in a registered direct offering. In addition, certain members of the Company's officers and directors are participating in the offering and have entered into definitive agreements for the purchase and sale of an aggregate of 731,707 shares of the Company's common stock and accompanying warrants to purchase up to an aggregate of 731,707 shares of the Company's common stock, at a purchase price of $1.435 per share and accompanying warrant.
2026-06-03 15:12:07
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript
2026-06-02 09:06:00
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
2026-06-01 16:01:00
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.
2026-05-21 17:00:00
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
2026-05-20 14:11:46
Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday said that it filed a lawsuit against Nerviano Medical Sciences (NMS), disputing NMS's claim that Cardiff materially breached their licensing agreement for onvansertib.
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
2026-05-14 16:10:00
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-28 16:01:00
SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, announced that in connection with Dr. Aggarwal joining Cardiff Oncology as Chief Operating Officer, the Company's Compensation Committee approved the grant of non-qualified stock options to purchase 400,000 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan.
Frequently Asked Questions
-
What is the current Cardiff Oncology, Inc. (CRDF) stock price?
-
Cardiff Oncology, Inc.(NASDAQ:CRDF) stock price is $0.8903 in the last trading session. During the trading session, CRDF stock reached the peak price of $4.56 while $0.83 was the lowest point it dropped to. The percentage change in CRDF stock occurred in the recent session was 0.11% while the dollar amount for the price change in CRDF stock was $0.0.
-
CRDF's industry and sector of operation?
-
The NASDAQ listed CRDF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRDF?
-
Josh Muntner | Chief Financial Officer
Brigitte Lindsay | Chief Accounting Officer
Ajay Aggarwal | Chief Operating Officer
Mani Mohindru | President, CEO & Director
Elizabeth Anderson | Vice President of Finance & Administration -
How many employees does CRDF have?
-
Number of CRDF employees currently stands at 31. CRDF operates from 11055 Flintkote Avenue, San Diego, CA 92121, US.
-
Link for CRDF official website?
-
Official Website of CRDF is: https://www.cardiffoncology.com
-
How do I contact CRDF?
-
CRDF could be contacted at phone #858 952 7570 and can also be accessed through its website. CRDF operates from 11055 Flintkote Avenue, San Diego, CA 92121, US.
-
How many shares of CRDF are traded daily?
-
The average number of CRDF shares traded daily for last 3 months was 1.41M.
-
What is the market cap of CRDF currently?
-
The market value of CRDF currently stands at $60.87M with its latest stock price at $0.8903